GSK · story · 27 October
GSK · 5 headlines from 5 outlets, on 27 October 2026.
A late-stage China study of ris-rez with Hansoh met its primary endpoint and delayed disease progression in bone cancer.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
FirstWord Pharma is the largest at 10.0, ahead of Reuters (10.0).
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| FirstWord Pharma | 10.0 |
| Reuters | 10.0 |
| Investing.com UK | 10.0 |
| Investing.com | 10.0 |
| TipRanks | 10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| FirstWord Pharma | 1 | +10.0 |
| Reuters | 1 | +10.0 |
| Investing.com UK | 1 | +10.0 |
| Investing.com | 1 | +10.0 |
| TipRanks | 1 | +10.0 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Trial showed large improvement in progression-free survival for bone cancer drug. |
| +10.0 | Late-stage China study showed slower disease progression. |
| +10.0 | GSK and Hansoh's drug prolonged survival in a bone-cancer trial. |
| +10.0 | A drug from GSK and Hansoh prolonged survival in a bone-cancer trial. |
| +10.0 | China trial achieved its main goal. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.